关注
Ayse Meric Ovacik
Ayse Meric Ovacik
在 gene.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
M Ovacik, K Lin
Clinical and translational science 11 (6), 540-552, 2018
2402018
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
K Staflin, CLZ de Zafra, LK Schutt, V Clark, F Zhong, M Hristopoulos, ...
JCI insight 5 (7), 2020
752020
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells
M Dillon, Y Yin, J Zhou, L McCarty, D Ellerman, D Slaga, TT Junttila, ...
MAbs 9 (2), 213-230, 2017
692017
Use of genomic data in risk assessment case study: II. Evaluation of the dibutyl phthalate toxicogenomic data set
SY Euling, LD White, AS Kim, B Sen, VS Wilson, C Keshava, N Keshava, ...
Toxicology and applied pharmacology 271 (3), 349-362, 2013
522013
Circadian signatures in rat liver: from gene expression to pathways
MA Ovacik, S Sukumaran, RR Almon, DC DuBois, WJ Jusko, ...
BMC bioinformatics 11, 1-15, 2010
332010
Logic-based and cellular pharmacodynamic modeling of bortezomib responses in U266 human myeloma cells
VL Chudasama, MA Ovacik, DR Abernethy, DE Mager
Journal of Pharmacology and Experimental Therapeutics 354 (3), 448-458, 2015
312015
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
S Kakiuchi-Kiyota, T Ross, HA Wallweber, JR Kiefer, MM Schutten, ...
Leukemia 36 (4), 1006-1014, 2022
242022
Transcriptional and metabolic flux profiling of triadimefon effects on cultured hepatocytes
VV Iyer, MA Ovacik, IP Androulakis, CM Roth, MG Ierapetritou
Toxicology and applied pharmacology 248 (3), 165-177, 2010
222010
Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties
AM Ovacik, J Li, M Lemper, D Danilenko, N Stagg, M Mathieu, D Ellerman, ...
MAbs 11 (2), 422-433, 2019
172019
Pathway modeling of microarray data: a case study of pathway activity changes in the testis following in utero exposure to dibutyl phthalate (DBP)
MA Ovacik, B Sen, SY Euling, KW Gaido, MG Ierapetritou, IP Androulakis
Toxicology and applied pharmacology 271 (3), 386-394, 2013
172013
On the potential for integrating gene expression and metabolic flux data
MA Ovacik, IP Androulakis
Current Bioinformatics 3 (3), 142-148, 2008
142008
Anti-LYPD1/CD3 T-cell-dependent bispecific antibody for the treatment of ovarian cancer
AA Lo, J Johnston, J Li, D Mandikian, M Hristopoulos, R Clark, D Nickles, ...
Molecular Cancer Therapeutics 20 (4), 716-725, 2021
112021
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity
S Ait-Oudhia, MA Ovacik, DE Mager
MAbs 9 (1), 15-28, 2017
102017
Novel anti-LY6G6D/CD3 T-cell–dependent bispecific antibody for the treatment of colorectal cancer
P Wang, LL Sun, R Clark, M Hristopoulos, CPC Chiu, M Dillon, WY Lin, ...
Molecular Cancer Therapeutics 21 (6), 974-985, 2022
92022
Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma
S Kakiuchi-Kiyota, MM Schutten, AO Adedeji, H Cai, R Hendricks, L Liu, ...
Cancer Res 80 (16Supplement), 4556, 2020
92020
Enzyme sequence similarity improves the reaction alignment method for cross-species pathway comparison
MA Ovacik, IP Androulakis
Toxicology and applied pharmacology 271 (3), 363-371, 2013
92013
Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma
H Cai, S Kakiuchi-Kiyota, R Hendricks, S Zhong, L Liu, AO Adedeji, ...
The AAPS Journal 24 (6), 100, 2022
82022
Nonclinical pharmacokinetics and pharmacodynamics characterization of anti-CD79B/CD3 T cell-dependent bispecific antibody using a surrogate molecule: a potential therapeutic …
R Yadav, S Sukumaran, TS Zabka, J Li, A Oldendorp, G Morrow, A Reyes, ...
Pharmaceutics 14 (5), 970, 2022
62022
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis
A Van De Vyver, M Eigenmann, M Ovacik, C Pohl, S Herter, T Weinzierl, ...
The AAPS Journal 24, 1-13, 2022
32022
An approach to using genomic data in risk assessment: Dibutyl phthalate (DBP) case study
SY Euling, L White, M Ovacik, S Makris, B Sen, IP Androulakis, S Hester, ...
Reproductive Toxicology 28 (2), 119, 2009
32009
系统目前无法执行此操作,请稍后再试。
文章 1–20